Brystkreft, ApoD og andre prognostiske faktorer - en klinisk, prognostisk og kvantitativ molekylærpatologisk studie.
- Prosjektnummer
- 911166
- Ansvarlig person
- Håvard Søiland
- Institusjon
- Helse Stavanger HF
- Prosjektkategori
- Forskerutdanning - dr.grad
- Helsekategori
- Surgery
- Forskningsaktivitet
- Klinisk forskning
Prognostic relevance of androgen receptor detection in operable breast cancer.
J Surg Oncol 2008;98(7):551-8.
PMID: 18937259
Androgen receptor determination in breast cancer: a comparison of the dextran-coated charcoal method and quantitative immunohistochemical analysis.
Appl Immunohistochem Mol Morphol 2008;16(4):362-70.
PMID: 18528280
Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
Acta Oncol 2009;48(4):514-21.
PMID: 19107621
Apolipoprotein D predicts adverse outcome in women >or=70 years with operable breast cancer.
Breast Cancer Res Treat 2009 Feb;113(3):519-28. Epub 2008 mar 11
PMID: 18330697
Comparison of apolipoprotein D determination methods in breast cancer.
Anticancer Res 2008 Mar-Apr;28(2B):1151-60.
PMID: 18505051
Emerging concepts of apolipoprotein D with possible implications for breast cancer.
Cell Oncol 2007;29(3):195-209.
PMID: 17452772
Androgen Receptor Determination in Breast Cancer: a comparison of the Dextran Coated Charcoal Method and Quantitative Immunohist
Akseptert Okt 2007 i Applied Immunihistochemistry & molecular morphology
Comparison of Apolipoprotein D Determination Methods in Breast Cancer
Akseptert Okt 2007 i Anticancer Research
Apolipoprotein D predicts adverse outcome In women over 70 years with operable breast cancer
In manus Jan 2008
The prognostic significance of ER-alfa in elderly patients with operable breast cancer is influenced by Apolipoprotein D
In manus Jan 2008
The long term prognostic value of Androgenreceptor in operable breast cancer patients
In manus Jan 2008
Apolipoprotein-D and Androgen Receptor in Operable Breast Cancer
- Disputert:
- oktober 2008
- Hovedveileder:
- Jon Arne Søreide
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Faglig rapportering, Helse Vest